Lumida
/WVE
⌘K
WAVE Life Sciences Ltd

WAVE Life Sciences Ltd

WVE
$4.59USD↓-1.71%-0.08 today

MARKET CAP

904.5M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$5 – $5

52W RANGE

$5
$22

AI Summary

Stalk
TrimMedium

In a Stage 4 decline, WVE remains under sustained seller control with price below all key EMAs and forming sequential lower highs and lower lows. Despite extreme oversold readings and a bearish exhaustion signal, no stable base has formed, and rallies continue to stall on muted volume. The medium-term bias is bearish, and sellers should defer new execution until rallies into resistance rather than selling into diminishing downside momentum.

  • ↑WVE-007 achieved placebo-adjusted 4% total fat and 9.2% visceral reduction at 240 mg dose over three months.
  • ↑Proprietary RNAi/editing technology targets inhibin E, preserving lean mass versus GLP-1 therapies.
  • ↓Q2 2026 net loss rose to $69.4 M from $50.5 M YoY, with R&D up to $51.3 M.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Wave Life Sciences Ltd. (NASDAQ: WVE) is a biotechnology company that focuses on developing innovative RNA-targeted therapies for significant unmet medical needs, notably in the areas of obesity and Alpha-1 Antitrypsin Deficiency (AATD). By leveraging its proprietary RNA interference and RNA editing technologies, Wave aims to redefine treatment paradigms, emphasizing effective fat loss and muscle preservation in obesity, while targeting the genetic basis for treating AATD. The company is in a growth phase with several key programs that position it competitively in the RNA therapeutic landscape.

Bull says

  • ↑WVE-007 achieved placebo-adjusted 4% total fat and 9.2% visceral reduction at 240 mg dose over three months.
  • ↑Proprietary RNAi/editing technology targets inhibin E, preserving lean mass versus GLP-1 therapies.
  • ↑Holds $544.6 M cash to fund operations into Q3 2028 without financing.
  • ↑GSK collaboration may deliver up to $2.8 B in milestone payments.
  • ↑Management plans FDA engagement for accelerated approval of WVE-006, expediting market access.
  • ↑High liquidity and strong institutional ownership provide price support amid volatility.

Bear says

  • ↓Q2 2026 net loss rose to $69.4 M from $50.5 M YoY, with R&D up to $51.3 M.
  • ↓Q2 revenue plunged to $2.3 M from $8.7 M, highlighting inconsistent income streams.
  • ↓Obesity market is crowded with Novo Nordisk and Eli Lilly GLP-1 therapies.
  • ↓Phase 2A results for WVE-007 are critical; any setback risks severe stock decline.
  • ↓Negative earnings yield and weak profitability suggest limited upside and high downside.
  • ↓Elevated volatility and small market size heighten susceptibility to external shocks.

Investment themes with WVE

Pharmaceuticals↓ -0.48%

Drug development driving global healthcare solutions

JNJ · LLY · RPRX
Weight Loss↓ -1.89%

Products and services targeting weight management

LLY · NVO · PFE

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-05-2026neutral

Transcript signals

Bull points

  • we're highly encouraged based on our preclinical models, based on our early proof of clinical mechanism data in translation.
  • GalNAC distribution, how that's distributing effectively to the cell type is behaving remarkably similar. So from an exposure standpoint, GalNAC is doing what it should be doing relative to these different modalities.
  • our team's modeling is getting more and more efficient about predicting those exposures.

Bear points

  • we have said that there are milestone payments that we can reasonably expect in 25, 26 from GSK.
  • Our revenue for the second quarter of 2025 was $8.7 million, compared to $19.7 million in the prior year quarter. The year-over-year decrease was attributable to the timing of revenue recognized under our collaboration agreement with GSK.
  • As a result, our net loss was $50.5 million for the second quarter of 2025, as compared to a net loss of $32.9 million in the prior year quarter.
Read full transcript analysis ›